The FDA on June 26, 2024, granted accelerated approval to EPKINLY®, a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory Follicular Lymphoma (FL) after two or more lines of systemic therapy. EPKINLY® is a product of Genmab US, Inc.
Bottom Ad
Advertisement
Subscribe
